造血干细胞动员的进展  

Advances in hematopoietic stem cell mobilization

作　　者：卓家才[1] 

机构地区：[1]深圳大学医学院第一附属医院深圳市第二人民医院血液科,518035

出　　处：《白血病．淋巴瘤》2013年第7期400-405,共6页Journal of Leukemia & Lymphoma

摘　　要：使用动员的外周血干细胞（PBSC）已经在很大程度上取代了骨髓作为干细胞源用于异基因和自体干细胞移植.粒细胞集落刺激因子（G-CSF）加或不加化疗是最常用的干细胞动员方案.一些供者或患者,特别是动员前经高强度治疗的患者,用这一方案不能动员到干细胞目标值.新动员剂和新疗法的产生能够改进造血干细胞的动员.Mobilized peripheral blood stem cells （PBSC） have largely replaced the use of bone marrow as a source of stem cells for both allogeneic and autologous stem cell transplantation.G-CSF with or without chemotherapy is the most commonly used regimen for stem cell mobilization.Some donors or patients,especially the heavily pretreated patients,fail to mobilize the targeted number of stem cells with this regimen.The generation of new mobilization agents and new therapies can improve the mobilization of hematopoietic stem cells.

关 键 词：造血干细胞 动员 

分 类 号：R329[医药卫生—人体解剖和组织胚胎学]